ID   CALR_HUMAN              Reviewed;         417 AA.
AC   P27797; Q6IAT4; Q9UDG2;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   03-AUG-2022, entry version 249.
DE   RecName: Full=Calreticulin {ECO:0000303|PubMed:9427624};
DE   AltName: Full=CRP55;
DE   AltName: Full=Calregulin;
DE   AltName: Full=Endoplasmic reticulum resident protein 60;
DE            Short=ERp60;
DE   AltName: Full=HACBP;
DE   AltName: Full=grp60;
DE   Flags: Precursor;
GN   Name=CALR {ECO:0000312|HGNC:HGNC:1455}; Synonyms=CRTC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2332496; DOI=10.1172/jci114582;
RA   McCauliffe D.P., Lux F.A., Lieu T.S., Sanz I., Hanke J., Newkirk M.M.,
RA   Bachinski L.L., Itoh Y., Siciliano M.J., Reichlin M., Sontheimer R.D.,
RA   Capra J.D.;
RT   "Molecular cloning, expression, and chromosome 19 localization of a human
RT   Ro/SS-A autoantigen.";
RL   J. Clin. Invest. 85:1379-1391(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1919005;
RA   Rokeach L.A., Haselby J.A., Meilof J.F., Smeenk R.J., Unnasch T.R.,
RA   Greene B.M., Hoch S.O.;
RT   "Characterization of the autoantigen calreticulin.";
RL   J. Immunol. 147:3031-3039(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1733953; DOI=10.1016/s0021-9258(18)45916-9;
RA   McCauliffe D.P., Yang Y.S., Wilson J., Sontheimer R.D., Capra J.D.;
RT   "The 5'-flanking region of the human calreticulin gene shares homology with
RT   the human GRP78, GRP94, and protein disulfide isomerase promoters.";
RL   J. Biol. Chem. 267:2557-2562(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Liu J., Peng X., Yuan J., Qiang B.;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye, Pancreas, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 18-48; 65-92; 96-114; 168-205 AND 257-354.
RC   TISSUE=Placenta;
RX   PubMed=7841019; DOI=10.3891/acta.chem.scand.48-0905;
RA   Houen G., Koch C.;
RT   "Human placental calreticulin: purification, characterization and
RT   association with other proteins.";
RL   Acta Chem. Scand. 48:905-911(1994).
RN   [12]
RP   PROTEIN SEQUENCE OF 18-41.
RX   PubMed=3260607; DOI=10.1172/jci113607;
RA   Lieu T.-S., Newkirk M.M., Capra J.D., Sontheimer R.D.;
RT   "Molecular characterization of human Ro/SS-A antigen. Amino terminal
RT   sequence of the protein moiety of human Ro/SS-A antigen and immunological
RT   activity of a corresponding synthetic peptide.";
RL   J. Clin. Invest. 82:96-101(1988).
RN   [13]
RP   PROTEIN SEQUENCE OF 18-36.
RX   PubMed=1911778; DOI=10.1021/bi00105a008;
RA   Rojiani M.V., Finlay B.B., Gray V., Dedhar S.;
RT   "In vitro interaction of a polypeptide homologous to human Ro/SS-A antigen
RT   (calreticulin) with a highly conserved amino acid sequence in the
RT   cytoplasmic domain of integrin alpha subunits.";
RL   Biochemistry 30:9859-9866(1991).
RN   [14]
RP   PROTEIN SEQUENCE OF 18-32.
RX   PubMed=2400400; DOI=10.1042/bj2700545;
RA   Krause K.-H., Simmerman H.K.B., Jones L.R., Campbell K.P.;
RT   "Sequence similarity of calreticulin with a Ca2(+)-binding protein that co-
RT   purifies with an Ins(1,4,5)P3-sensitive Ca2+ store in HL-60 cells.";
RL   Biochem. J. 270:545-548(1990).
RN   [15]
RP   PROTEIN SEQUENCE OF 18-28.
RC   TISSUE=Liver;
RX   PubMed=1286669; DOI=10.1002/elps.11501301201;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RT   "Human liver protein map: a reference database established by
RT   microsequencing and gel comparison.";
RL   Electrophoresis 13:992-1001(1992).
RN   [16]
RP   PROTEIN SEQUENCE OF 25-36; 74-111 AND 208-222, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [17]
RP   PROTEIN SEQUENCE OF 25-34; 56-62; 208-221 AND 273-278.
RC   TISSUE=Keratinocyte;
RX   PubMed=1286667; DOI=10.1002/elps.11501301199;
RA   Rasmussen H.H., van Damme J., Puype M., Gesser B., Celis J.E.,
RA   Vandekerckhove J.;
RT   "Microsequences of 145 proteins recorded in the two-dimensional gel protein
RT   database of normal human epidermal keratinocytes.";
RL   Electrophoresis 13:960-969(1992).
RN   [18]
RP   PROTEIN SEQUENCE OF 18-27, AND SUBCELLULAR LOCATION.
RX   PubMed=8418194; DOI=10.1084/jem.177.1.1;
RA   Dupuis M., Schaerer E., Krause K.-H., Tschopp J.;
RT   "The calcium-binding protein calreticulin is a major constituent of lytic
RT   granules in cytolytic T lymphocytes.";
RL   J. Exp. Med. 177:1-7(1993).
RN   [19]
RP   PROTEIN SEQUENCE OF 18-26.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [20]
RP   FUNCTION.
RX   PubMed=7876246; DOI=10.1074/jbc.270.9.4741;
RA   Nauseef W.M., McCormick S.J., Clark R.A.;
RT   "Calreticulin functions as a molecular chaperone in the biosynthesis of
RT   myeloperoxidase.";
RL   J. Biol. Chem. 270:4741-4747(1995).
RN   [21]
RP   INTERACTION WITH TRIM21.
RX   PubMed=8666824;
RA   Cheng S.T., Nguyen T.Q., Yang Y.S., Capra J.D., Sontheimer R.D.;
RT   "Calreticulin binds hYRNA and the 52-kDa polypeptide component of the
RT   Ro/SS-A ribonucleoprotein autoantigen.";
RL   J. Immunol. 156:4484-4491(1996).
RN   [22]
RP   SUBUNIT, AND INTERACTION WITH HLA-E.
RX   PubMed=9427624; DOI=10.1016/s0960-9822(98)70014-4;
RA   Braud V.M., Allan D.S., Wilson D., McMichael A.J.;
RT   "TAP- and tapasin-dependent HLA-E surface expression correlates with the
RT   binding of an MHC class I leader peptide.";
RL   Curr. Biol. 8:1-10(1998).
RN   [23]
RP   SUBUNIT, AND INTERACTION WITH HLA-G.
RX   PubMed=9640257; DOI=10.1046/j.1365-2567.1998.00439.x;
RA   Wainwright S.D., Simpson K.L., Holmes C.H.;
RT   "Calreticulin associates with non-HLA-A,-B class I proteins in the human
RT   choriocarcinoma cell lines JEG-3 and BeWo.";
RL   Immunology 93:437-445(1998).
RN   [24]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10358038; DOI=10.1074/jbc.274.24.16917;
RA   Arosa F.A., de Jesus O., Porto G., Carmo A.M., de Sousa M.;
RT   "Calreticulin is expressed on the cell surface of activated human
RT   peripheral blood T lymphocytes in association with major histocompatibility
RT   complex class I molecules.";
RL   J. Biol. Chem. 274:16917-16922(1999).
RN   [25]
RP   SUBUNIT, AND INTERACTION WITH HLA-F.
RX   PubMed=10605026; DOI=10.4049/jimmunol.164.1.319;
RA   Wainwright S.D., Biro P.A., Holmes C.H.;
RT   "HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib
RT   protein with a restricted expression pattern.";
RL   J. Immunol. 164:319-328(2000).
RN   [26]
RP   FUNCTION, INTERACTION WITH NR3C1, SUBCELLULAR LOCATION, AND MASS
RP   SPECTROMETRY.
RX   PubMed=11149926; DOI=10.1083/jcb.152.1.127;
RA   Holaska J.M., Black B.E., Love D.C., Hanover J.A., Leszyk J., Paschal B.M.;
RT   "Calreticulin is a receptor for nuclear export.";
RL   J. Cell Biol. 152:127-140(2001).
RN   [27]
RP   PARTIAL PROTEIN SEQUENCE, DISULFIDE BOND, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Placenta;
RX   PubMed=11322874; DOI=10.1046/j.1432-1327.2001.02138.x;
RA   Hoejrup P., Roepstorff P., Houen G.;
RT   "Human placental calreticulin characterization of domain structure and
RT   post-translational modifications.";
RL   Eur. J. Biochem. 268:2558-2565(2001).
RN   [28]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-344.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-48; LYS-159 AND LYS-209, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [30]
RP   INTERACTION WITH PPIB.
RX   PubMed=20801878; DOI=10.1074/jbc.m110.160101;
RA   Kozlov G., Bastos-Aristizabal S., Maattanen P., Rosenauer A., Zheng F.,
RA   Killikelly A., Trempe J.F., Thomas D.Y., Gehring K.;
RT   "Structural basis of cyclophilin B binding by the calnexin/calreticulin P-
RT   domain.";
RL   J. Biol. Chem. 285:35551-35557(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [33]
RP   INTERACTION WITH PDIA5.
RX   PubMed=23614004; DOI=10.1371/journal.pone.0062021;
RA   Vinaik R., Kozlov G., Gehring K.;
RT   "Structure of the non-catalytic domain of the protein disulfide isomerase-
RT   related protein (PDIR) reveals function in protein binding.";
RL   PLoS ONE 8:E62021-E62021(2013).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   CLEAVAGE OF SIGNAL PEPTIDE [LARGE SCALE ANALYSIS] AFTER ALA-17, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [36]
RP   HYDROXYBUTYRYLATION AT LYS-64.
RX   PubMed=29192674; DOI=10.1038/cr.2017.149;
RA   Huang H., Luo Z., Qi S., Huang J., Xu P., Wang X., Gao L., Li F., Wang J.,
RA   Zhao W., Gu W., Chen Z., Dai L., Dai J., Zhao Y.;
RT   "Landscape of the regulatory elements for lysine 2-hydroxyisobutyrylation
RT   pathway.";
RL   Cell Res. 28:111-125(2018).
RN   [37]
RP   INTERACTION WITH CLCC1.
RX   PubMed=30157172; DOI=10.1371/journal.pgen.1007504;
RA   Li L., Jiao X., D'Atri I., Ono F., Nelson R., Chan C.C., Nakaya N., Ma Z.,
RA   Ma Y., Cai X., Zhang L., Lin S., Hameed A., Chioza B.A., Hardy H., Arno G.,
RA   Hull S., Khan M.I., Fasham J., Harlalka G.V., Michaelides M., Moore A.T.,
RA   Coban Akdemir Z.H., Jhangiani S., Lupski J.R., Cremers F.P.M., Qamar R.,
RA   Salman A., Chilton J., Self J., Ayyagari R., Kabir F., Naeem M.A., Ali M.,
RA   Akram J., Sieving P.A., Riazuddin S., Baple E.L., Riazuddin S.A.,
RA   Crosby A.H., Hejtmancik J.F.;
RT   "Mutation in the intracellular chloride channel CLCC1 associated with
RT   autosomal recessive retinitis pigmentosa.";
RL   PLoS Genet. 14:E1007504-E1007504(2018).
RN   [38]
RP   INVOLVEMENT IN MYELOPROLIFERATIVE NEOPLASMS.
RX   PubMed=24325356; DOI=10.1056/nejmoa1311347;
RA   Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E.,
RA   Milosevic J.D., Them N.C., Berg T., Gisslinger B., Pietra D., Chen D.,
RA   Vladimer G.I., Bagienski K., Milanesi C., Casetti I.C., Sant'Antonio E.,
RA   Ferretti V., Elena C., Schischlik F., Cleary C., Six M., Schalling M.,
RA   Schoenegger A., Bock C., Malcovati L., Pascutto C., Superti-Furga G.,
RA   Cazzola M., Kralovics R.;
RT   "Somatic mutations of calreticulin in myeloproliferative neoplasms.";
RL   N. Engl. J. Med. 369:2379-2390(2013).
RN   [39]
RP   INVOLVEMENT IN MYELOPROLIFERATIVE NEOPLASMS.
RX   PubMed=24325359; DOI=10.1056/nejmoa1312542;
RA   Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C.,
RA   Avezov E., Li J., Kollmann K., Kent D.G., Aziz A., Godfrey A.L., Hinton J.,
RA   Martincorena I., Van Loo P., Jones A.V., Guglielmelli P., Tarpey P.,
RA   Harding H.P., Fitzpatrick J.D., Goudie C.T., Ortmann C.A., Loughran S.J.,
RA   Raine K., Jones D.R., Butler A.P., Teague J.W., O'Meara S., McLaren S.,
RA   Bianchi M., Silber Y., Dimitropoulou D., Bloxham D., Mudie L., Maddison M.,
RA   Robinson B., Keohane C., Maclean C., Hill K., Orchard K., Tauro S.,
RA   Du M.Q., Greaves M., Bowen D., Huntly B.J.P., Harrison C.N., Cross N.C.P.,
RA   Ron D., Vannucchi A.M., Papaemmanuil E., Campbell P.J., Green A.R.;
RT   "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated
RT   JAK2.";
RL   N. Engl. J. Med. 369:2391-2405(2013).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 195-205 IN COMPLEX WITH GABARAP,
RP   AND INTERACTION WITH GABARAP.
RX   PubMed=19154346; DOI=10.1111/j.1742-4658.2008.06857.x;
RA   Thielmann Y., Weiergraber O.H., Mohrluder J., Willbold D.;
RT   "Structural framework of the GABARAP-calreticulin interface -- implications
RT   for substrate binding to endoplasmic reticulum chaperones.";
RL   FEBS J. 276:1140-1152(2009).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 18-368 IN COMPLEX WITH CALCIUM
RP   IONS, AND DISULFIDE BOND.
RX   PubMed=21423620; DOI=10.1371/journal.pone.0017886;
RA   Chouquet A., Paidassi H., Ling W.L., Frachet P., Houen G., Arlaud G.J.,
RA   Gaboriaud C.;
RT   "X-ray structure of the human calreticulin globular domain reveals a
RT   peptide-binding area and suggests a multi-molecular mechanism.";
RL   PLoS ONE 6:E17886-E17886(2011).
CC   -!- FUNCTION: Calcium-binding chaperone that promotes folding, oligomeric
CC       assembly and quality control in the endoplasmic reticulum (ER) via the
CC       calreticulin/calnexin cycle. This lectin interacts transiently with
CC       almost all of the monoglucosylated glycoproteins that are synthesized
CC       in the ER (PubMed:7876246). Interacts with the DNA-binding domain of
CC       NR3C1 and mediates its nuclear export (PubMed:11149926). Involved in
CC       maternal gene expression regulation. May participate in oocyte
CC       maturation via the regulation of calcium homeostasis (By similarity).
CC       Present in the cortical granules of non-activated oocytes, is
CC       exocytosed during the cortical reaction in response to oocyte
CC       activation and might participate in the block to polyspermy (By
CC       similarity). {ECO:0000250|UniProtKB:P28491,
CC       ECO:0000250|UniProtKB:Q8K3H7, ECO:0000269|PubMed:11149926,
CC       ECO:0000269|PubMed:7876246}.
CC   -!- SUBUNIT: Monomer. Component of an EIF2 complex at least composed of
CC       CELF1/CUGBP1, CALR, CALR3, EIF2S1, EIF2S2, HSP90B1 and HSPA5. Interacts
CC       with PDIA3/ERp57 and SPACA9 (By similarity). Interacts with TRIM21
CC       (PubMed:8666824). Interacts with NR3C1 (PubMed:11149926). Interacts
CC       with PPIB (PubMed:20801878). Interacts (via P-domain) with PDIA5
CC       (PubMed:23614004). Interacts with GABARAP (PubMed:19154346). Interacts
CC       with HLA-E-B2M and HLA-G-B2M complexes (PubMed:9427624,
CC       PubMed:9640257). Interacts with HLA-F (PubMed:10605026). Interacts with
CC       CLCC1 (PubMed:30157172). {ECO:0000250|UniProtKB:P14211,
CC       ECO:0000250|UniProtKB:P18418, ECO:0000269|PubMed:10605026,
CC       ECO:0000269|PubMed:11149926, ECO:0000269|PubMed:19154346,
CC       ECO:0000269|PubMed:20801878, ECO:0000269|PubMed:23614004,
CC       ECO:0000269|PubMed:30157172, ECO:0000269|PubMed:8666824,
CC       ECO:0000269|PubMed:9427624, ECO:0000269|PubMed:9640257}.
CC   -!- INTERACTION:
CC       P27797; P05067: APP; NbExp=5; IntAct=EBI-1049597, EBI-77613;
CC       P27797; Q8N1W1-4: ARHGEF28; NbExp=3; IntAct=EBI-1049597, EBI-13062134;
CC       P27797; Q8TAB5: C1orf216; NbExp=3; IntAct=EBI-1049597, EBI-747505;
CC       P27797; O94983-5: CAMTA2; NbExp=3; IntAct=EBI-1049597, EBI-10176008;
CC       P27797; O75175: CNOT3; NbExp=3; IntAct=EBI-1049597, EBI-743073;
CC       P27797; Q6UXH1-2: CRELD2; NbExp=3; IntAct=EBI-1049597, EBI-21670927;
CC       P27797; P49184: DNASE1L1; NbExp=3; IntAct=EBI-1049597, EBI-20894690;
CC       P27797; Q8IY82: DRC7; NbExp=3; IntAct=EBI-1049597, EBI-10262896;
CC       P27797; Q99944: EGFL8; NbExp=3; IntAct=EBI-1049597, EBI-3924130;
CC       P27797; P16422: EPCAM; NbExp=3; IntAct=EBI-1049597, EBI-1171184;
CC       P27797; Q9NVM1: EVA1B; NbExp=3; IntAct=EBI-1049597, EBI-10314666;
CC       P27797; Q96GK7: FAHD2A; NbExp=3; IntAct=EBI-1049597, EBI-21647872;
CC       P27797; Q10981: FUT2; NbExp=3; IntAct=EBI-1049597, EBI-9090702;
CC       P27797; O95166: GABARAP; NbExp=4; IntAct=EBI-1049597, EBI-712001;
CC       P27797; P36382: GJA5; NbExp=3; IntAct=EBI-1049597, EBI-750433;
CC       P27797; P09471: GNAO1; NbExp=3; IntAct=EBI-1049597, EBI-715087;
CC       P27797; O15499: GSC2; NbExp=3; IntAct=EBI-1049597, EBI-19954058;
CC       P27797; P79483: HLA-DRB3; NbExp=3; IntAct=EBI-1049597, EBI-3910269;
CC       P27797; P14060: HSD3B1; NbExp=3; IntAct=EBI-1049597, EBI-17426018;
CC       P27797; P04792: HSPB1; NbExp=2; IntAct=EBI-1049597, EBI-352682;
CC       P27797; Q7Z6Z7-2: HUWE1; NbExp=3; IntAct=EBI-1049597, EBI-10975491;
CC       P27797; O75874: IDH1; NbExp=3; IntAct=EBI-1049597, EBI-715695;
CC       P27797; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-1049597, EBI-2557660;
CC       P27797; A0JP07: KIAA1683; NbExp=3; IntAct=EBI-1049597, EBI-10171456;
CC       P27797; P26715: KLRC1; NbExp=3; IntAct=EBI-1049597, EBI-9018187;
CC       P27797; Q6P5S2: LEG1; NbExp=3; IntAct=EBI-1049597, EBI-11750531;
CC       P27797; P09382: LGALS1; NbExp=3; IntAct=EBI-1049597, EBI-1048875;
CC       P27797; O00214-2: LGALS8; NbExp=3; IntAct=EBI-1049597, EBI-12069522;
CC       P27797; P43356: MAGEA2B; NbExp=3; IntAct=EBI-1049597, EBI-5650739;
CC       P27797; Q7Z434: MAVS; NbExp=3; IntAct=EBI-1049597, EBI-995373;
CC       P27797; P11226: MBL2; NbExp=6; IntAct=EBI-1049597, EBI-5325353;
CC       P27797; Q8NCR3: MFI; NbExp=3; IntAct=EBI-1049597, EBI-744790;
CC       P27797; Q8TB02: MGC39372; NbExp=3; IntAct=EBI-1049597, EBI-25834188;
CC       P27797; Q96EY8: MMAB; NbExp=3; IntAct=EBI-1049597, EBI-7825413;
CC       P27797; P48039: MTNR1A; NbExp=3; IntAct=EBI-1049597, EBI-1188238;
CC       P27797; A2RUH7: MYBPHL; NbExp=3; IntAct=EBI-1049597, EBI-9088235;
CC       P27797; Q9NPC7: MYNN; NbExp=3; IntAct=EBI-1049597, EBI-3446748;
CC       P27797; Q9HC98-4: NEK6; NbExp=3; IntAct=EBI-1049597, EBI-11750983;
CC       P27797; Q8NCF5-2: NFATC2IP; NbExp=3; IntAct=EBI-1049597, EBI-12305293;
CC       P27797; Q96P20: NLRP3; NbExp=3; IntAct=EBI-1049597, EBI-6253230;
CC       P27797; Q8N323: NXPE1; NbExp=3; IntAct=EBI-1049597, EBI-25834085;
CC       P27797; Q6P4D5-2: PABIR3; NbExp=3; IntAct=EBI-1049597, EBI-9091052;
CC       P27797; Q8N2W9: PIAS4; NbExp=3; IntAct=EBI-1049597, EBI-473160;
CC       P27797; Q8NBT0: POC1A; NbExp=3; IntAct=EBI-1049597, EBI-2557132;
CC       P27797; O14829: PPEF1; NbExp=3; IntAct=EBI-1049597, EBI-2931238;
CC       P27797; Q96QH2: PRAM1; NbExp=3; IntAct=EBI-1049597, EBI-2860740;
CC       P27797; Q9Y617: PSAT1; NbExp=3; IntAct=EBI-1049597, EBI-709652;
CC       P27797; P43686: PSMC4; NbExp=3; IntAct=EBI-1049597, EBI-743997;
CC       P27797; Q13200: PSMD2; NbExp=3; IntAct=EBI-1049597, EBI-357648;
CC       P27797; Q9Y3Y4: PYGO1; NbExp=3; IntAct=EBI-1049597, EBI-3397474;
CC       P27797; Q13636: RAB31; NbExp=3; IntAct=EBI-1049597, EBI-725987;
CC       P27797; Q96E17: RAB3C; NbExp=3; IntAct=EBI-1049597, EBI-4287022;
CC       P27797; P61224: RAP1B; NbExp=3; IntAct=EBI-1049597, EBI-358143;
CC       P27797; P50749: RASSF2; NbExp=3; IntAct=EBI-1049597, EBI-960081;
CC       P27797; Q96I25: RBM17; NbExp=3; IntAct=EBI-1049597, EBI-740272;
CC       P27797; P52756: RBM5; NbExp=3; IntAct=EBI-1049597, EBI-714003;
CC       P27797; Q96EQ0: SGTB; NbExp=3; IntAct=EBI-1049597, EBI-744081;
CC       P27797; Q02978: SLC25A11; NbExp=3; IntAct=EBI-1049597, EBI-359174;
CC       P27797; Q12824: SMARCB1; NbExp=5; IntAct=EBI-1049597, EBI-358419;
CC       P27797; Q3SY56: SP6; NbExp=3; IntAct=EBI-1049597, EBI-11175533;
CC       P27797; Q96L03: SPATA17; NbExp=3; IntAct=EBI-1049597, EBI-13322423;
CC       P27797; Q7Z698: SPRED2; NbExp=3; IntAct=EBI-1049597, EBI-7082156;
CC       P27797; Q53T94: TAF1B; NbExp=3; IntAct=EBI-1049597, EBI-1560239;
CC       P27797; Q03518: TAP1; NbExp=2; IntAct=EBI-1049597, EBI-747259;
CC       P27797; F6Y2X3: TAZ; NbExp=3; IntAct=EBI-1049597, EBI-25833693;
CC       P27797; P48775: TDO2; NbExp=3; IntAct=EBI-1049597, EBI-743494;
CC       P27797; Q9BQ29: THAP4; NbExp=3; IntAct=EBI-1049597, EBI-22013570;
CC       P27797; Q9BT49: THAP7; NbExp=3; IntAct=EBI-1049597, EBI-741350;
CC       P27797; P49746: THBS3; NbExp=3; IntAct=EBI-1049597, EBI-2530931;
CC       P27797; Q96JJ7-2: TMX3; NbExp=3; IntAct=EBI-1049597, EBI-25833898;
CC       P27797; Q9H2S6-2: TNMD; NbExp=3; IntAct=EBI-1049597, EBI-12003398;
CC       P27797; Q68CL5-3: TPGS2; NbExp=3; IntAct=EBI-1049597, EBI-9091010;
CC       P27797; Q9ULW0: TPX2; NbExp=3; IntAct=EBI-1049597, EBI-1037322;
CC       P27797; Q9NX07: TRNAU1AP; NbExp=3; IntAct=EBI-1049597, EBI-12581310;
CC       P27797; P07437: TUBB; NbExp=3; IntAct=EBI-1049597, EBI-350864;
CC       P27797; Q7Z780: U2AF1; NbExp=3; IntAct=EBI-1049597, EBI-25833730;
CC       P27797; O75317: USP12; NbExp=3; IntAct=EBI-1049597, EBI-2511507;
CC       P27797; Q96EF9: ZHX1-C8orf76; NbExp=3; IntAct=EBI-1049597, EBI-25830993;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum lumen
CC       {ECO:0000269|PubMed:10358038, ECO:0000269|PubMed:11149926}. Cytoplasm,
CC       cytosol {ECO:0000269|PubMed:11149926}. Secreted, extracellular space,
CC       extracellular matrix {ECO:0000305}. Cell surface
CC       {ECO:0000269|PubMed:10358038}. Sarcoplasmic reticulum lumen
CC       {ECO:0000250|UniProtKB:P28491}. Cytoplasmic vesicle, secretory vesicle,
CC       Cortical granule {ECO:0000250|UniProtKB:Q8K3H7}. Cytolytic granule
CC       {ECO:0000269|PubMed:8418194}. Note=Also found in cell surface (T
CC       cells), cytosol and extracellular matrix (PubMed:10358038). During
CC       oocyte maturation and after parthenogenetic activation accumulates in
CC       cortical granules. In pronuclear and early cleaved embryos localizes
CC       weakly to cytoplasm around nucleus and more strongly in the region near
CC       the cortex (By similarity). In cortical granules of non-activated
CC       oocytes, is exocytosed during the cortical reaction in response to
CC       oocyte activation (By similarity). {ECO:0000250|UniProtKB:P28491,
CC       ECO:0000250|UniProtKB:Q8K3H7, ECO:0000269|PubMed:8418194}.
CC   -!- DOMAIN: Can be divided into a N-terminal globular domain, a proline-
CC       rich P-domain forming an elongated arm-like structure and a C-terminal
CC       acidic domain. The P-domain binds one molecule of calcium with high
CC       affinity, whereas the acidic C-domain binds multiple calcium ions with
CC       low affinity.
CC   -!- DOMAIN: The interaction with glycans occurs through a binding site in
CC       the globular lectin domain.
CC   -!- DOMAIN: The zinc binding sites are localized to the N-domain.
CC   -!- DOMAIN: Associates with PDIA3 through the tip of the extended arm
CC       formed by the P-domain.
CC   -!- MASS SPECTROMETRY: Mass=46879; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:11149926};
CC   -!- DISEASE: Note=CALR somatic mutations are frequently found in
CC       myeloproliferative neoplasms lacking JAK2 or MPL mutations.
CC       Myeloproliferative neoplasms are chronic myeloid cancers characterized
CC       by overproduction of mature blood cells, and may evolve into acute
CC       myeloid leukemia. In addition to chronic myeloid leukemia with the BCR-
CC       ABL fusion gene, the three most common myeloproliferative neoplasms are
CC       essential thrombocythemia, polycythemia vera, and myelofibrosis.
CC       {ECO:0000269|PubMed:24325356, ECO:0000269|PubMed:24325359}.
CC   -!- SIMILARITY: Belongs to the calreticulin family. {ECO:0000305}.
CC   -!- CAUTION: Was originally thought to be the 52 kDa Ro autoantigen.
CC       {ECO:0000305|PubMed:2332496}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Calreticulin entry;
CC       URL="https://en.wikipedia.org/wiki/Calreticulin";
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Calreticulin;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_other_405";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M32294; AAA36582.1; -; mRNA.
DR   EMBL; M84739; AAA51916.1; -; mRNA.
DR   EMBL; AY047586; AAL13126.1; -; mRNA.
DR   EMBL; AB451408; BAG70222.1; -; mRNA.
DR   EMBL; BT007448; AAP36116.1; -; mRNA.
DR   EMBL; CR457070; CAG33351.1; -; mRNA.
DR   EMBL; AD000092; AAB51176.1; -; Genomic_DNA.
DR   EMBL; CH471106; EAW84331.1; -; Genomic_DNA.
DR   EMBL; BC002500; AAH02500.1; -; mRNA.
DR   EMBL; BC007911; AAH07911.1; -; mRNA.
DR   EMBL; BC020493; AAH20493.1; -; mRNA.
DR   CCDS; CCDS12288.1; -.
DR   PIR; A42330; A37047.
DR   RefSeq; NP_004334.1; NM_004343.3.
DR   PDB; 2CLR; X-ray; 2.00 A; C/F=1-10.
DR   PDB; 3DOW; X-ray; 2.30 A; B=195-205.
DR   PDB; 3POS; X-ray; 1.65 A; A/B/C=18-204, A/B/C=302-368.
DR   PDB; 3POW; X-ray; 1.55 A; A=18-204, A=302-368.
DR   PDB; 5LK5; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J=18-204, A/B/C/D/E/F/G/H/I/J=303-368.
DR   PDB; 5V90; X-ray; 3.25 A; B/D=238-273.
DR   PDB; 6ENY; EM; 5.80 A; G=18-417.
DR   PDBsum; 2CLR; -.
DR   PDBsum; 3DOW; -.
DR   PDBsum; 3POS; -.
DR   PDBsum; 3POW; -.
DR   PDBsum; 5LK5; -.
DR   PDBsum; 5V90; -.
DR   PDBsum; 6ENY; -.
DR   AlphaFoldDB; P27797; -.
DR   BMRB; P27797; -.
DR   SMR; P27797; -.
DR   BioGRID; 107262; 367.
DR   CORUM; P27797; -.
DR   DIP; DIP-104N; -.
DR   IntAct; P27797; 164.
DR   MINT; P27797; -.
DR   STRING; 9606.ENSP00000320866; -.
DR   DrugBank; DB00025; Antihemophilic factor, human recombinant.
DR   DrugBank; DB11093; Calcium citrate.
DR   DrugBank; DB11348; Calcium Phosphate.
DR   DrugBank; DB14481; Calcium phosphate dihydrate.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB13949; Ferric cation.
DR   DrugBank; DB06245; Lanoteplase.
DR   DrugBank; DB13998; Lonoctocog alfa.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB13999; Moroctocog alfa.
DR   DrugBank; DB00031; Tenecteplase.
DR   DrugBank; DB14520; Tetraferric tricitrate decahydrate.
DR   MoonProt; P27797; -.
DR   UniLectin; P27797; -.
DR   GlyConnect; 1060; 10 N-Linked glycans (1 site).
DR   GlyGen; P27797; 2 sites, 10 N-linked glycans (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; P27797; -.
DR   MetOSite; P27797; -.
DR   PhosphoSitePlus; P27797; -.
DR   SwissPalm; P27797; -.
DR   BioMuta; CALR; -.
DR   DMDM; 117501; -.
DR   DOSAC-COBS-2DPAGE; P27797; -.
DR   OGP; P27797; -.
DR   REPRODUCTION-2DPAGE; IPI00020599; -.
DR   SWISS-2DPAGE; P27797; -.
DR   UCD-2DPAGE; P27797; -.
DR   CPTAC; CPTAC-33; -.
DR   CPTAC; CPTAC-34; -.
DR   CPTAC; CPTAC-698; -.
DR   EPD; P27797; -.
DR   jPOST; P27797; -.
DR   MassIVE; P27797; -.
DR   PaxDb; P27797; -.
DR   PeptideAtlas; P27797; -.
DR   PRIDE; P27797; -.
DR   ProteomicsDB; 54410; -.
DR   TopDownProteomics; P27797; -.
DR   ABCD; P27797; 3 sequenced antibodies.
DR   Antibodypedia; 1028; 1147 antibodies from 47 providers.
DR   CPTC; P27797; 1 antibody.
DR   DNASU; 811; -.
DR   Ensembl; ENST00000316448.10; ENSP00000320866.4; ENSG00000179218.15.
DR   Ensembl; ENST00000586967.2; ENSP00000466037.2; ENSG00000179218.15.
DR   GeneID; 811; -.
DR   KEGG; hsa:811; -.
DR   MANE-Select; ENST00000316448.10; ENSP00000320866.4; NM_004343.4; NP_004334.1.
DR   CTD; 811; -.
DR   DisGeNET; 811; -.
DR   GeneCards; CALR; -.
DR   HGNC; HGNC:1455; CALR.
DR   HPA; ENSG00000179218; Low tissue specificity.
DR   MalaCards; CALR; -.
DR   MIM; 109091; gene.
DR   neXtProt; NX_P27797; -.
DR   OpenTargets; ENSG00000179218; -.
DR   Orphanet; 131; Budd-Chiari syndrome.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 824; Primary myelofibrosis.
DR   PharmGKB; PA26046; -.
DR   VEuPathDB; HostDB:ENSG00000179218; -.
DR   eggNOG; KOG0674; Eukaryota.
DR   GeneTree; ENSGT00950000182915; -.
DR   HOGENOM; CLU_018224_0_2_1; -.
DR   InParanoid; P27797; -.
DR   OMA; MMWCKTV; -.
DR   OrthoDB; 822188at2759; -.
DR   PhylomeDB; P27797; -.
DR   TreeFam; TF338438; -.
DR   PathwayCommons; P27797; -.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-168316; Assembly of Viral Components at the Budding Site.
DR   Reactome; R-HSA-3000480; Scavenging by Class A Receptors.
DR   Reactome; R-HSA-3000484; Scavenging by Class F Receptors.
DR   Reactome; R-HSA-381183; ATF6 (ATF6-alpha) activates chaperone genes.
DR   Reactome; R-HSA-901042; Calnexin/calreticulin cycle.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   SignaLink; P27797; -.
DR   BioGRID-ORCS; 811; 28 hits in 1097 CRISPR screens.
DR   ChiTaRS; CALR; human.
DR   EvolutionaryTrace; P27797; -.
DR   GeneWiki; Calreticulin; -.
DR   GenomeRNAi; 811; -.
DR   Pharos; P27797; Tbio.
DR   PRO; PR:P27797; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P27797; protein.
DR   Bgee; ENSG00000179218; Expressed in stromal cell of endometrium and 203 other tissues.
DR   ExpressionAtlas; P27797; baseline and differential.
DR   Genevisible; P27797; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; TAS:BHF-UCL.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; IEA:Ensembl.
DR   GO; GO:0060473; C:cortical granule; ISS:UniProtKB.
DR   GO; GO:0044194; C:cytolytic granule; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0044322; C:endoplasmic reticulum quality control compartment; IEA:Ensembl.
DR   GO; GO:0033116; C:endoplasmic reticulum-Golgi intermediate compartment membrane; TAS:Reactome.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IMP:CAFA.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0071556; C:integral component of lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0042824; C:MHC class I peptide loading complex; IDA:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0030670; C:phagocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005844; C:polysome; IDA:BHF-UCL.
DR   GO; GO:0033018; C:sarcoplasmic reticulum lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0030246; F:carbohydrate binding; TAS:BHF-UCL.
DR   GO; GO:0051087; F:chaperone binding; TAS:BHF-UCL.
DR   GO; GO:0001849; F:complement component C1q complex binding; TAS:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0042562; F:hormone binding; IEA:Ensembl.
DR   GO; GO:0005178; F:integrin binding; IPI:BHF-UCL.
DR   GO; GO:0005506; F:iron ion binding; IEA:Ensembl.
DR   GO; GO:0003729; F:mRNA binding; IDA:BHF-UCL.
DR   GO; GO:0050681; F:nuclear androgen receptor binding; IDA:BHF-UCL.
DR   GO; GO:0042277; F:peptide binding; IEA:Ensembl.
DR   GO; GO:0044183; F:protein folding chaperone; TAS:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; TAS:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; TAS:BHF-UCL.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; TAS:UniProtKB.
DR   GO; GO:0071257; P:cellular response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0071285; P:cellular response to lithium ion; IEA:Ensembl.
DR   GO; GO:0098586; P:cellular response to virus; IEA:Ensembl.
DR   GO; GO:0090398; P:cellular senescence; IGI:BHF-UCL.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0042921; P:glucocorticoid receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0033144; P:negative regulation of intracellular steroid hormone receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IDA:BHF-UCL.
DR   GO; GO:0048387; P:negative regulation of retinoic acid receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:BHF-UCL.
DR   GO; GO:1901164; P:negative regulation of trophoblast cell migration; IMP:CAFA.
DR   GO; GO:0002502; P:peptide antigen assembly with MHC class I protein complex; ISS:BHF-UCL.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IGI:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IGI:BHF-UCL.
DR   GO; GO:2000510; P:positive regulation of dendritic cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:CAFA.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; ISS:BHF-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0006611; P:protein export from nucleus; IDA:UniProtKB.
DR   GO; GO:0006457; P:protein folding; IBA:GO_Central.
DR   GO; GO:0034975; P:protein folding in endoplasmic reticulum; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0034504; P:protein localization to nucleus; IDA:UniProtKB.
DR   GO; GO:0022417; P:protein maturation by protein folding; TAS:BHF-UCL.
DR   GO; GO:0050821; P:protein stabilization; ISS:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0040020; P:regulation of meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:1903416; P:response to glycoside; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0051208; P:sequestering of calcium ion; TAS:BHF-UCL.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0030433; P:ubiquitin-dependent ERAD pathway; IBA:GO_Central.
DR   Gene3D; 2.10.250.10; -; 1.
DR   InterPro; IPR001580; Calret/calnex.
DR   InterPro; IPR018124; Calret/calnex_CS.
DR   InterPro; IPR009169; Calreticulin.
DR   InterPro; IPR009033; Calreticulin/calnexin_P_dom_sf.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   PANTHER; PTHR11073; PTHR11073; 1.
DR   Pfam; PF00262; Calreticulin; 2.
DR   PIRSF; PIRSF002356; Calreticulin; 1.
DR   PRINTS; PR00626; CALRETICULIN.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   SUPFAM; SSF63887; SSF63887; 1.
DR   PROSITE; PS00803; CALRETICULIN_1; 1.
DR   PROSITE; PS00804; CALRETICULIN_2; 1.
DR   PROSITE; PS00805; CALRETICULIN_REPEAT; 3.
DR   PROSITE; PS00014; ER_TARGET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Calcium; Chaperone; Cytoplasm;
KW   Cytoplasmic vesicle; Direct protein sequencing; Disulfide bond;
KW   Endoplasmic reticulum; Extracellular matrix; Glycoprotein; Hydroxylation;
KW   Lectin; Lysosome; Metal-binding; Reference proteome; Repeat;
KW   Sarcoplasmic reticulum; Secreted; Signal; Zinc.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000269|PubMed:1286669,
FT                   ECO:0000269|PubMed:1911778, ECO:0000269|PubMed:2400400,
FT                   ECO:0000269|PubMed:3260607, ECO:0000269|PubMed:7841019,
FT                   ECO:0000269|PubMed:8418194, ECO:0000269|PubMed:9150948,
FT                   ECO:0007744|PubMed:25944712"
FT   CHAIN           18..417
FT                   /note="Calreticulin"
FT                   /id="PRO_0000004173"
FT   REPEAT          191..202
FT                   /note="1-1"
FT   REPEAT          210..221
FT                   /note="1-2"
FT   REPEAT          227..238
FT                   /note="1-3"
FT   REPEAT          244..255
FT                   /note="1-4"
FT   REPEAT          259..269
FT                   /note="2-1"
FT   REPEAT          273..283
FT                   /note="2-2"
FT   REPEAT          287..297
FT                   /note="2-3"
FT   REGION          18..197
FT                   /note="N-domain"
FT   REGION          191..255
FT                   /note="4 X approximate repeats"
FT   REGION          193..278
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          198..308
FT                   /note="P-domain"
FT   REGION          237..270
FT                   /note="Interaction with PPIB"
FT                   /evidence="ECO:0000250"
FT   REGION          259..297
FT                   /note="3 X approximate repeats"
FT   REGION          309..417
FT                   /note="C-domain"
FT   REGION          350..417
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           414..417
FT                   /note="Prevents secretion from ER"
FT   COMPBIAS        199..254
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        352..381
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        382..417
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         26
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         62
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         64
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   BINDING         109
FT                   /ligand="an alpha-D-glucoside"
FT                   /ligand_id="ChEBI:CHEBI:22390"
FT                   /evidence="ECO:0000250|UniProtKB:P14211"
FT   BINDING         111
FT                   /ligand="an alpha-D-glucoside"
FT                   /ligand_id="ChEBI:CHEBI:22390"
FT                   /evidence="ECO:0000250|UniProtKB:P14211"
FT   BINDING         128
FT                   /ligand="an alpha-D-glucoside"
FT                   /ligand_id="ChEBI:CHEBI:22390"
FT                   /evidence="ECO:0000250|UniProtKB:P14211"
FT   BINDING         135
FT                   /ligand="an alpha-D-glucoside"
FT                   /ligand_id="ChEBI:CHEBI:22390"
FT                   /evidence="ECO:0000250|UniProtKB:P14211"
FT   BINDING         317
FT                   /ligand="an alpha-D-glucoside"
FT                   /ligand_id="ChEBI:CHEBI:22390"
FT                   /evidence="ECO:0000250|UniProtKB:P14211"
FT   BINDING         328
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT   MOD_RES         48
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         64
FT                   /note="N6-(2-hydroxyisobutyryl)lysine"
FT                   /evidence="ECO:0000269|PubMed:29192674"
FT   MOD_RES         159
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         209
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   CARBOHYD        344
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   DISULFID        105..137
FT                   /evidence="ECO:0000269|PubMed:11322874,
FT                   ECO:0000269|PubMed:21423620"
FT   STRAND          20..25
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   HELIX           30..35
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          37..39
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          42..44
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          49..52
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   TURN            60..63
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          65..68
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          70..84
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          91..98
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          104..107
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          110..113
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   HELIX           119..121
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          129..138
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          142..150
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          153..156
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          166..176
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          180..186
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          189..195
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   HELIX           196..199
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:3DOW"
FT   TURN            255..257
FT                   /evidence="ECO:0007829|PDB:5V90"
FT   TURN            303..306
FT                   /evidence="ECO:0007829|PDB:5LK5"
FT   STRAND          311..322
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   STRAND          326..334
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   HELIX           336..345
FT                   /evidence="ECO:0007829|PDB:3POW"
FT   HELIX           347..366
FT                   /evidence="ECO:0007829|PDB:3POW"
SQ   SEQUENCE   417 AA;  48142 MW;  BC37C3C0F1054FB2 CRC64;
     MLLSVPLLLG LLGLAVAEPA VYFKEQFLDG DGWTSRWIES KHKSDFGKFV LSSGKFYGDE
     EKDKGLQTSQ DARFYALSAS FEPFSNKGQT LVVQFTVKHE QNIDCGGGYV KLFPNSLDQT
     DMHGDSEYNI MFGPDICGPG TKKVHVIFNY KGKNVLINKD IRCKDDEFTH LYTLIVRPDN
     TYEVKIDNSQ VESGSLEDDW DFLPPKKIKD PDASKPEDWD ERAKIDDPTD SKPEDWDKPE
     HIPDPDAKKP EDWDEEMDGE WEPPVIQNPE YKGEWKPRQI DNPDYKGTWI HPEIDNPEYS
     PDPSIYAYDN FGVLGLDLWQ VKSGTIFDNF LITNDEAYAE EFGNETWGVT KAAEKQMKDK
     QDEEQRLKEE EEDKKRKEEE EAEDKEDDED KDEDEEDEED KEEDEEEDVP GQAKDEL
//
